However, the final pooled results are statistically significant and the authors concluded that "dietary vitamin B2 intake is weakly related to the reduced risk of breast cancer". This should be treated with caution because the results would be unstable-when omitting the study by Cancarini et al.
To the editor,
We read with great interest of the recently published article named "Dietary vitamin B2 intake and breast cancer risk: a systematic review and meta-analysis" by Yu et al. [1] , and would like to discuss it with our own opinion. Generally, the systematic review was clearly designed and conducted, while several points may influence the quality of this study.
First, we notice that the authors only searched Medline for eligible studies, this is not recommended due to the potential risk of missing detection of studies. As the Cochrane handbook suggested, at least two databases (e.g. Medline, Embase) should be searched when conducting a systematic review or meta-analysis [2] . Second, the authors claimed they uses PRISMA-P [3] to undertake their meta-analysis, while this is not appropriate since PRISMA-P is designed for guiding authors to develop a protocol of systematic review or meta-analysis instead of systematic review or meta-analysis itself [3] . Third, the authors combined the OR/RR from the highest quantile to detect the potential influence of vitamin B2 on breast cancer and got statistically significant pooled results (RR = 0.85, 95% CI: 0.76, 0.95). This method, to some extent, is invalid because the "level" of highest quantile of vitamin B2 varies across studies (from 1.16 to 9.52) making the pooled result of heterogeneous. Fourth, in the table the authors listed all the HR/RR corresponding to each quantile of vitamin B2 on breast cancer, and only one study by Cancarini et al. [4] showed that dietary vitamin B2 may reduce the risk of breast cancer but not other nine studies.
